News Zai Lab Limited Börse Stuttgart

Equities

1ZL

US98887Q1040

Real-time Estimate Tradegate Other stock markets 02:14:33 2024-07-01 pm EDT			5-day change	1st Jan Change
16.05 ^EUR	-1.53%		-5.78%	-33.20%

Jun. 27	Zai Lab Insider Sold Shares Worth $428,532, According to a Recent SEC Filing	MT
Jun. 20	Zai Lab Grants ADSs to Independent Directors Under Incentive Scheme	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Zai Lab Insider Sold Shares Worth $428,532, According to a Recent SEC Filing	Jun. 27	MT
Zai Lab : Argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropath	Jun. 21	PU
Zai Lab Grants ADSs to Independent Directors Under Incentive Scheme	Jun. 20	MT
Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Friday Trading	Jun. 14	MT
Transcript : Zai Lab Limited Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 01:20 PM	Jun. 12
Zai Lab Limited Announces Executive Changes, Effective June 30, 2024	Jun. 11	CI
Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D	Jun. 11	BU
Tech, Financial Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday	Jun. 04	MT
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Lower	May. 24	MT
Zai Lab Doses First Patient in a Phase 2 Clinical Trial of Plaque Psoriasis Treatment; Shares Rise	May. 22	MT
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis	May. 22	BU
Zai Lab Limited Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis	May. 22	CI
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	May. 21	AQ
Chinese Regulator Approves Zai Lab’s New Drug Application for Bacterial Pneumonia Drug	May. 20	MT
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment	May. 20	MT
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	May. 20	BU
Zai Lab and Innoviva Specialty Therapeutics Announces NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China	May. 20	CI
Asian Equities Traded in the US as American Depositary Receipts Ease in Thursday Trading	May. 16	MT
Zai Lab Announces Participation in May and June Investor Conferences	May. 16	BU
Zai Lab's Supplemental Application for Autoimmune Disease Treatment Accepted by China Regulator	May. 14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Zai Lab Limited Börse Stuttgart

Equities

1ZL

US98887Q1040

Summary

Filters